You are here

Theranostic Virtual Reality Headset for Amblyopia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41EY028466-01A1
Agency Tracking Number: R41EY028466
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NEI
Solicitation Number: PA17-303
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
Newton, MA 02459-3605
United States
DUNS: 078739650
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (413) 336-3464
Business Contact
Phone: (617) 755-3838
Research Institution
CHICAGO, IL 60611-3152
United States

 Nonprofit College or University

Amblyopia is the most common cause of monocular visual impairment in children and young adultsaffectingpeopleAmblyopia is generally treated with patching or atropine therapyhowever these treatments are
not effective in adults and up to half of juvenile casesoften because of poor complianceand cannot easily be
personalized during therapyThese factors have led to recent interest in customized game based binocular
therapies that are administered inD entertainment systemsTypically functional endpoints are assessed with
behavioral tasks that must be learned by the patient and interrupt the delivery of therapyNeuroFieldz and Northeastern University have developed a new product NeuroDotVR combining a wireless
NeuroDot sensor to measure Visual Evoked Potentials and FieldsVEPFwith a Virtual Reality headset powered
by a smartphone to generate visual stimuliIn this Phase I STTR projectwe propose to use the NeuroDotVR
product with Swept Contrast VEPFSC VEPFas an objectivenon invasive endpoint to measure treatment
responseSC VEPF stimuli will be embedded within the therapeutic stimuli without requiring the patient to
perform any task and enabling uninterrupted delivery of therapyThe project aims areSpecific AimMeasurement of the Contrast Sensitivity Function with the SC VEPF We will measure
the SC VEPF in the impaired and fellow eyes ofamblyopic adults andamblyopic children by recording the
VEPF amplitudes to filtered noise stimuli as a function of contrastNoise stimuli will be presented independently
to each eye using the SC VEPF systemWe will systematically vary the peak spatial frequency of the noise
stimuliorcycles per degreeand contrastand vary the temporal frequency fromtoHzand
measure VEPF amplitude to estimate the contrast sensitivity function of each eyeWe hypothesize that
compared to the fellow eyethe amblyopic eye will have attenuated VEPF amplitudesespecially at high spatial
frequenciesand that the magnitude of the inter ocular difference will vary with temporal frequencySpecific AimDiagnostic SC VEPF Embedded within Therapeutic Stimuli To minimize interruption of
therapywe propose to embed the diagnostic filtered noise stimulitocycles per degreewithin the
therapeutic stimuliHollywood movies with broad spatio temporal spectrumTo reduce contamination between
the diagnostic and therapeutic stimulithe therapeutic stimuli will be digitally notch filtered with a spatio temporal
filter that removes all spatial and temporal frequencies within one octave of the test spatio temporal frequencySC VEPF will be measured in the impaired and fellow eye ofamblyopic adults andamblyopic children and
behavioral estimates of contrast sensitivity will be collected with the same stimuliWe hypothesize that patients
will not object to the diagnostic noise embedded in the therapy stimuli and that compared to the fellow eyethe
amblyopic eye will have attenuated VEPF amplitudes and behaviorally estimated contrast sensitivityespecially
at high spatial frequencies Project TitleTheranostic Virtual Reality Headset for AmblyopiaAmblyopia is an eye disorder that affects approximatelyM in the USThis project will
develop a virtual reality headset that administers visual therapies and simultaneously evaluates
response to treatment by measuring visual evoked potentialsIf successfulthe system will
provide a new rapidconvenient method providing quantitative endpoints monitoring response to
newly developed treatments

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government